Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys

被引:95
作者
Masarachia, Patricia J. [1 ]
Pennypacker, Brenda L. [1 ]
Pickarski, Maureen [1 ]
Scott, Kevin R. [1 ]
Wesolowski, Gregg A. [1 ]
Smith, Susan Y. [3 ]
Samadfam, Rani [3 ]
Goetzmann, Jason E. [4 ]
Scott, Boyd B. [2 ]
Kimmel, Donald B. [1 ]
Duong, Le T. [1 ]
机构
[1] Merck Sharp & Dohme Corp, Bone Biol Grp, West Point, PA USA
[2] Merck Sharp & Dohme Corp, Global Sci & Med Publicat, N Wales, PA USA
[3] Charles River Labs, Preclin Serv, Montreal, PQ, Canada
[4] Univ Louisiana Lafayette, New Iberia Res Ctr, New Iberia, LA USA
关键词
OSTEOPENIA; CATHEPSIN K INHIBITOR; OSTEOCLAST; NONHUMAN PRIMATE; OSTEOPOROSIS; CATHEPSIN-K INHIBITOR; RESISTANT ACID-PHOSPHATASE; CORTICAL BONE; POSTMENOPAUSAL WOMEN; RESORPTION; STRENGTH; MARKERS; ALENDRONATE; DENSITY; MICE;
D O I
10.1002/jbmr.1475
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin K (CatK) currently being developed as a once-weekly treatment for osteoporosis. In this study, we evaluated the effects of ODN on bone turnover, bone mineral density (BMD), and bone strength in the lumbar spine of estrogen-deficient, skeletally mature rhesus monkeys. Ovariectomized (OVX) monkeys were treated in prevention mode for 21 months with either vehicle, ODN 6?mg/kg, or ODN 30?mg/kg (p.o., q.d.) and compared with intact animals. ODN treatment persistently suppressed the bone resorption markers (urinary NTx [75% to 90%] and serum CTx [40% to 55%]) and the serum formation markers (BSAP [30% to 35%] and P1NP [60% to 70%]) versus vehicle-treated OVX monkeys. Treatment with ODN also led to dose-dependent increases in serum 1-CTP and maintained estrogen deficiencyelevated Trap-5b levels, supporting the distinct mechanism of CatK inhibition in effectively suppressing bone resorption without reducing osteoclast numbers. ODN at both doses fully prevented bone loss in lumbar vertebrae (L1 to L4) BMD in OVX animals, maintaining a level comparable to intact animals. ODN dose-dependently increased L1 to L4 BMD by 7% in the 6?mg/kg group (p?<?0.05 versus OVX-vehicle) and 15% in the 30?mg/kg group (p?<?0.05 versus OVX-vehicle) from baseline. Treatment also trended to increase bone strength, associated with a positive and highly significant correlation (R?=?0.838) between peak load and bone mineral content of the lumbar spine. Whereas ODN reduced bone turnover parameters in trabecular bone, the number of osteoclasts was either maintained or increased in the ODN-treated groups compared with the vehicle controls. Taken together, our findings demonstrated that the long-term treatment with ODN effectively suppressed bone turnover without reducing osteoclast number and maintained normal biomechanical properties of the spine of OVX nonhuman primates. (c) 2012 American Society for Bone and Mineral Research
引用
收藏
页码:509 / 523
页数:15
相关论文
共 47 条
[1]
THE EFFECTS OF 2-YEAR TREATMENT WITH THE AMINOBISPHOSPHONATE ALENDRONATE ON BONE METABOLISM, BONE HISTOMORPHOMETRY, AND BONE STRENGTH IN OVARIECTOMIZED NONHUMAN-PRIMATES [J].
BALENA, R ;
TOOLAN, BC ;
SHEA, M ;
MARKATOS, A ;
MYERS, ER ;
LEE, SC ;
OPAS, EE ;
SEEDOR, JG ;
KLEIN, H ;
FRANKENFIELD, D ;
QUARTUCCIO, H ;
FIORAVANTI, C ;
CLAIR, J ;
BROWN, E ;
HAYES, WC ;
RODAN, GA .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2577-2586
[2]
Binkley N, 1999, LAB ANIM SCI, V49, P87
[3]
Bone HG, 2011, J BONE MINER RES, V26, P242
[4]
Cabal A, BONE S1, V47
[5]
Cabal A, 2009, J BONE MINER RES S1
[6]
The Cathepsin K Inhibitor AAE581 Induces Morphological Changes in Osteoclasts of Treated Patients [J].
Chappard, Daniel ;
Libouban, Helene ;
Mindeholm, Linda ;
Basle, Michel F. ;
Legrand, Erick ;
Audran, Maurice .
MICROSCOPY RESEARCH AND TECHNIQUE, 2010, 73 (07) :726-732
[7]
Cusick TE, 2009, J BONE MINER RES S1, V24
[8]
Potential new drug targets for osteoporosis [J].
Deal, Chad .
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2009, 5 (01) :20-27
[9]
The bone lining cell:: Its role in cleaning Howship's lacunae and initiating bone formation [J].
Everts, V ;
Delaissé, JM ;
Korper, W ;
Jansen, DC ;
Tigchelaar-Gutter, W ;
Saftig, P ;
Beertsen, W .
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (01) :77-90
[10]
Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys [J].
Fox, J. ;
Miller, M. A. ;
Newman, M. K. ;
Recker, R. R. ;
Turner, C. H. ;
Smith, S. Y. .
BONE, 2007, 41 (03) :321-330